As managing director of BioRN, Dr. Julia Schaft sits at the center of one of Europe's most powerful biotech ecosystems — connecting world-class research institutions, startups, and 9 of the top 20 global pharma companies within the Heidelberg region. In this episode, she unpacks why Europe keeps losing biotech companies to the US, how Germany's risk-averse culture holds back innovation, and what it actually takes to turn academic science into real products.
Dr. Julia Schaft is the Managing Director of BioRN, the biotech cluster covering Heidelberg and the broader Rhein-Neckar region. She holds a PhD from EMBL and has spent over a decade building bridges between academia, industry, and policy to strengthen Germany's life science ecosystem.
📥 We distilled the sharpest lessons from our first 6 guests into one free guide — the Insider Biotech Career Starter Pack. Get it at https://transcribedpod.com
Julia explains:

◼️ Why Europe has dropped from #2–3 to #7–8 globally in clinical trials — and how bureaucracy and slow processes are driving startups to the US

◼️ The "valley of death" problem: German startups get funded at the seed stage but struggle to find capital for preclinical development

◼️ Why "Americans tend to overpromise and Europeans tend to undersell" — and what that means for European science

◼️ Her honest take on AI in life sciences: "The ultimate proof that it's actually really working is still out there"

◼️ How BioRN grew from 70–80 members to 185 by creating genuine win-win collaborations instead of funding-driven alliances

00:00 Welcome to Transcribed

00:44 What Is BioRN? How a Biotech Cluster Works

01:40 A Day in the Life of a Managing Director

03:58 What Startups, Pharma, and Academia Need from BioRN

05:20 From Lab Bench to Ecosystem Builder: Julia's Career Shift

06:55 What Makes Heidelberg a Top European Biotech Hub

08:35 The Biggest Obstacles to Translating Science into Products

11:00 Is Europe Falling Behind the US and China?

13:00 Venture Capital and Risk Culture: Europe vs. America

15:40 How to Get Competitors to Actually Collaborate17:20 Talent Retention: "We Don't Need to Attract Them — We Need to Keep Them"

18:35 BioRN's Growth: From 80 Members to 185

20:07 Scientist by Heart, Networker by Evolution

21:18 AI in Life Sciences: Promise vs. Proof

23:10 Advice for Young Scientists Considering Industry

25:01 Will AI Take Away Jobs in Biotech?

26:00 Closing

Follow Julia:LinkedIn - https://www.linkedin.com/in/julia-schaft-409396a/

---
Transcribed Podcast — in-person interviews with scientists, founders, and industry experts shaping the future of biotech and pharma.
🎙️ Watch all episodes: https://www.youtube.com/@TranscribedPod📥 Free Biotech Starter Pack → https://transcribedpod.com🌐 https://transcribedpod.com📸 Instagram: @transcribedpod📧 [email protected]

#TranscribedPodcast #Biotech #Pharma #Science #Interview #BioRN #Heidelberg #Startups #VentureCapital #Innovation

From dreaming of becoming a pilot to engineering proteins with light, Prof. Dr. Dominik Niopek sits at the cutting edge of programmable biology — building tools that let scientists control gene editing with a laser beam. In this episode, he walks us through how CRISPR went from a test tube experiment to an FDA-approved therapy in just 12 years, why humanoid robots might soon asist PhD students at the lab bench, and how AI is reshaping everything from protein design to how we educate the next generation of scientists.Prof. Dr. Dominik Niopek is a professor and group leader at Heidelberg University, where he runs a ~20-person lab specializing in optogenetics, CRISPR engineering, and AI-driven protein design. His work focuses on using light-sensitive proteins to precisely control genome editing and cellular processes, bridging synthetic biology and therapeutic application.Dominik explains:◼️ How his lab fuses light-sensing proteins to CRISPR tools — activating genome editing by shining a laser on a single point inside a cell◼️ Why CRISPR going from test tube to FDA-approved therapy in 12 years is "almost incomparable to anything else" in science◼️ Why humanoid robots at ~50–100K each could transform academic labs faster than traditional automation◼️ His bold vision: outsource all foundational university teaching to AI tutors so professors can focus on creative, project-based collaboration◼️ The internal reproducibility rule his lab enforces — and why it has produced near-zero complaints from collaborators00:00 Welcome to Transcribed00:45 The Boy Who Wanted to Be a Pilot02:39 The Moment Science Became an Obsession04:47 Why Scientists Should Play Piano07:15 iGEM: The Competition That Changed His Life09:58 A Day in the Life of a Professor12:06 What Is Optogenetics? Controlling Cells with Light15:09 How Running a Lab Changes as You Grow17:16 AI in the Lab: From AlphaFold to De Novo Protein Design20:39 Will AI Replace University Professors?25:00 The Hidden Risk of Trusting a Single AI27:00 CRISPR: The Biggest Biotech Revolution of Our Time30:36 The Future Lab: Humanoid Robots at the Bench33:06 The Reproducibility Crisis Is Not Over38:31 Career Advice: Follow Your Curiosity, Build Your Network40:49 ClosingFollow Dominik:LinkedIn - https://www.linkedin.com/in/dominik-niopek-796775b5/—Transcribed Podcast — in-person interviews with scientists, founders, and industry experts shaping the future of biotech and pharma.🎙️ Watch all episodes: https://www.youtube.com/@TranscribedPod🌐 transcribedpod.com📸 Instagram: @transcribedpod📧 [email protected]#TranscribedPodcast #Biotech #Pharma #Science #Interview #CRISPR #Optogenetics #GeneTherapy #AI #Heidelberg

In this episode, we sit down with Dr. Abdelrahman Mahmoud, CEO & Founder of CellRewire, to explore a bold new vision for medicine: predictive and reprogrammable biology. What if AI could read the language of our cells, predict disease years before it emerges, and even reprogram cells back to a healthy state? We dive into CellRewire's groundbreaking Cell-DRL agent (Cellular Deep Reinforcement Learning), how it generates novel reprogramming therapies, and how AI can design targeted gene programs and interventions to guide diseased cells back to health.Whether you're into biotech, AI, or the future of medicine, this one's for you.Learn more about CellRewire: https://www.cellrewire.comLearn more about Transcribed: https://transcribedpod.com

In this episode we sit down with the CEO of PEPperPRINT Volker Stadler to explore how affordable peptide micro-arrays change the landscape of vaccine development, biotech research and more.

Find us on all platforms:https://linktr.ee/transcribed_podcast#innovation

#peptides #PEPperPRINT #biotech #transcribed #transcribed volker stadler #volker #stadler #Volker Stadler #podcast #biotech podcast #students #antibody #research #startup #pharma

In this episode, we sit down with Dr. Axel Schumacher to cover topics such as ageing, epigenetics and AI.

In this episode of our biotech podcast, we sit down with Patrick Most – biotech entrepreneur, founder of Aavigen, and professor of cardiology in Heidelberg University, Germany. Together, we explore his journey, insights into gene therapy, and how it will change the therapeutic landscape.Hosted by Meronn and Pierre00:00:00 Intro00:01:40 Why gene therapy?00:03:20 From Academia to Biotech00:12:20 pitching a startup00:13:30 pitfalls when translating academic findings00:17:00 Accessibility of gene therapy00:19:40 Viruses to cure diseases???00:28:00 AI in gene therapy00:30:40 Business model00:34:05 Clearing misconceptions00:36:10 Patience as a biotech founder00:43:10 Day to day as professor and biotech founder00:45:00 Spinning out early or later?00:47:00 The role of a CEO00:51:35 Choosing Co-Founders00:54:10 Corona00:56:00 Biotech winter00:58:30 Networking01:01:00 How to get started as a student01:02:45 Impact of being a CEO on professor and vice versa01:05:00 US vs. Germany01:08:00 Doing something differently?01:10:03 When will Gene therapy cure heart disease?01:13:00 Conclusion#genetherapy #biotechnology #PatrickMost #transcribed #AAV #virus #research #professor #Heidelberg #innovation

In this episode of our biotech podcast, we sit down with Christian Tidona – biotech entrepreneur, founder of BioMed X, and a key figure shaping the future of life sciences in Germany. Together, we explore his journey, insights into biotech innovation, and the intersection of science, business, and impact.Hosted by Meronn and PierreTimecodes:00:00 - From Lab to Venture: Christian Tidona’s Origin Story03:10 - Failing and perseverence05:00 - Choosing Co‑Founders: Trust Over Superstars06:15 - Mentors10:00 - Underestimating founding a company11:25 - Business plan competitions13:25 - Preparing to be lucky15:00 - Trusting the right people17:46 - Growing a company20:00 - VC vs Privately owned25:00 - Scaling: Shifts from 5 to 50+ Employees26:30 - Networking30:00 - Work–Life Integration for Founders31:00 - Academia vs Industry vs Entrepreneurship33:10 - Typical day of an entrepreneur?35:00 - Crisis Playbook: When Experiments (or Equipment) don’t work35:30 - 80% focus 20% exploration37:20 - Do it all over again38:30 - Development of the Heidelberg region40:00 - BioRegio to BioMed X: Building Heidelberg’s Biotech Hub42:30 - Allergic to mediocrity44:55 - Spotting High‑Potential46:10 - Long-term perspectiveSubscribe for more conversations with pioneers in biotech and beyond.#Biotech #ChristianTidona #BioMedX #SciencePodcast #Startup